
    
      The study is a multicenter, multicountry, randomized, parallel-group, double blind, placebo
      and paroxetine-controlled study consisting of three segments (A, B, and C). Segment A is a
      1-week, placebo, single-blind period and Segment B is an 8-week, double blind period. All
      randomized patients must complete a post-study visit 1 week after intake of the last dose of
      study medication.
    
  